Artwork

Innhold levert av Dr Neil Love. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Dr Neil Love eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Chronic Lymphocytic Leukemia | Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences

1:34:58
 
Del
 

Manage episode 412230738 series 1464352
Innhold levert av Dr Neil Love. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Dr Neil Love eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Featuring perspectives from Dr Bita Fakhri, including the following topics:

  • Overview of select presentations from ASH 2023; recent FDA approval of lisocabtagene maraleucel (0:00)
  • 6-year follow-up from the Phase III CLL14 trial of first-line venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for chronic lymphocytic leukemia (CLL) (7:36)
  • Updates from ASH 2023 from the Phase III FLAIR study of minimal residual disease (MRD)-guided ibrutinib in combination with venetoclax for previously untreated CLL (13:28)
  • 57-month follow-up from the Phase III GLOW trial of fixed-duration ibrutinib/venetoclax for previously untreated CLL (22:28)
  • Current clinical role of MRD testing for CLL (28:11)
  • Key findings from 5-year follow-up of the Phase II CAPTIVATE study for patents with CLL/small lymphocytic leukemia (SLL) with relapse after first-line fixed-duration ibrutinib/venetoclax (36:43)
  • 6-year update from the Phase III ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for treatment-naïve CLL (41:57)
  • Updates from ASH 2023 for the management of relapsed/refractory CLL (54:30)
  • Recent updates for the management of double-refractory CLL (58:05)
  • Novel therapies under investigation for patients with CLL/SLL (1:10:57)
  • Key findings guiding the clinical management of Richter’s transformation (1:13:44)
  • Case: A man in his early 80s with IGHV-unmutated del(17p) CLL experiences disease progression 3 years after completing second-line venetoclax-based therapy (1:22:17)

CME information and select publications

  continue reading

1340 episoder

Artwork
iconDel
 
Manage episode 412230738 series 1464352
Innhold levert av Dr Neil Love. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Dr Neil Love eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Featuring perspectives from Dr Bita Fakhri, including the following topics:

  • Overview of select presentations from ASH 2023; recent FDA approval of lisocabtagene maraleucel (0:00)
  • 6-year follow-up from the Phase III CLL14 trial of first-line venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for chronic lymphocytic leukemia (CLL) (7:36)
  • Updates from ASH 2023 from the Phase III FLAIR study of minimal residual disease (MRD)-guided ibrutinib in combination with venetoclax for previously untreated CLL (13:28)
  • 57-month follow-up from the Phase III GLOW trial of fixed-duration ibrutinib/venetoclax for previously untreated CLL (22:28)
  • Current clinical role of MRD testing for CLL (28:11)
  • Key findings from 5-year follow-up of the Phase II CAPTIVATE study for patents with CLL/small lymphocytic leukemia (SLL) with relapse after first-line fixed-duration ibrutinib/venetoclax (36:43)
  • 6-year update from the Phase III ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for treatment-naïve CLL (41:57)
  • Updates from ASH 2023 for the management of relapsed/refractory CLL (54:30)
  • Recent updates for the management of double-refractory CLL (58:05)
  • Novel therapies under investigation for patients with CLL/SLL (1:10:57)
  • Key findings guiding the clinical management of Richter’s transformation (1:13:44)
  • Case: A man in his early 80s with IGHV-unmutated del(17p) CLL experiences disease progression 3 years after completing second-line venetoclax-based therapy (1:22:17)

CME information and select publications

  continue reading

1340 episoder

Все серии

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett